多发性硬化症的口服疗法——是重大变革还是渐进式进展？ - Suppr

Suppr

超能文献

Oral therapy for multiple sclerosis--sea change or incremental step?

作者信息

Carroll William M

出版信息

N Engl J Med. 2010 Feb 4;362(5):456-8. doi: 10.1056/NEJMe0912019. Epub 2010 Jan 20.

DOI:10.1056/NEJMe0912019

PMID:20089958

Abstract

摘要

相似文献

Oral therapy for multiple sclerosis--sea change or incremental step?

N Engl J Med. 2010 Feb 4;362(5):456-8. doi: 10.1056/NEJMe0912019. Epub 2010 Jan 20.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

Neurology. 2012 Mar 20;78(12):928-30. doi: 10.1212/WNL.0b013e31824c46ad. Epub 2012 Mar 7.

Oral cladribine and fingolimod for relapsing multiple sclerosis.

N Engl J Med. 2010 May 6;362(18):1738; author reply 1739-40. doi: 10.1056/NEJMc1002550.

Fingolimod for the treatment of relapsing multiple sclerosis.

Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16.

Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.

N Engl J Med. 2006 Sep 14;355(11):1088-91. doi: 10.1056/NEJMp068159.

Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.

J Neurol Sci. 2011 Dec;311 Suppl 1:S29-34. doi: 10.1016/S0022-510X(11)70006-5.

New drugs may improve, complicate treatment for multiple sclerosis.

Nat Med. 2010 Mar;16(3):272. doi: 10.1038/nm0310-272.

Sudden unexpected death on fingolimod.

Mult Scler. 2012 Oct;18(10):1507-8. doi: 10.1177/1352458512438456. Epub 2012 Feb 2.

引用本文的文献

Expression of leukotriene B receptor 1 defines functionally distinct DCs that control allergic skin inflammation.

Cell Mol Immunol. 2021 Jun;18(6):1437-1449. doi: 10.1038/s41423-020-00559-7. Epub 2020 Oct 9.

Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis.

Degener Neurol Neuromuscul Dis. 2012 Mar 10;2:15-28. doi: 10.2147/DNND.S29022. eCollection 2012.

Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases.

Manage Sci. 2018 Aug;64(8):3469-3970. doi: 10.1287/mnsc.2017.2793. Epub 2017 Aug 21.

Celastrol Ameliorates EAE Induction by Suppressing Pathogenic T Cell Responses in the Peripheral and Central Nervous Systems.

J Neuroimmune Pharmacol. 2015 Sep;10(3):506-16. doi: 10.1007/s11481-015-9598-9. Epub 2015 Mar 15.

New hope for multiple sclerosis patients.

ACS Chem Neurosci. 2013 Mar 20;4(3):368. doi: 10.1021/cn400059g.

MS Treatment Is on the Cusp of Something Big: On the Cusp of Something Big?

Biotechnol Healthc. 2012 Winter;9(4):24-7.

Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Br J Pharmacol. 2012 Apr;165(7):2044-58. doi: 10.1111/j.1476-5381.2011.01762.x.

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis.

J Pharmacol Pharmacother. 2011 Jan;2(1):49-51. doi: 10.4103/0976-500X.77118.

Lipid phosphate phosphatase 3 enables efficient thymic egress.

J Exp Med. 2011 Jun 6;208(6):1267-78. doi: 10.1084/jem.20102551. Epub 2011 May 16.

Prevalence of celiac disease in multiple sclerosis.

BMC Neurol. 2011 Mar 7;11:31. doi: 10.1186/1471-2377-11-31.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Oral therapy for multiple sclerosis--sea change or incremental step?

N Engl J Med. 2010 Feb 4;362(5):456-8. doi: 10.1056/NEJMe0912019. Epub 2010 Jan 20.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?

Neurology. 2012 Mar 20;78(12):928-30. doi: 10.1212/WNL.0b013e31824c46ad. Epub 2012 Mar 7.

Oral cladribine and fingolimod for relapsing multiple sclerosis.

N Engl J Med. 2010 May 6;362(18):1738; author reply 1739-40. doi: 10.1056/NEJMc1002550.

Fingolimod for the treatment of relapsing multiple sclerosis.

Expert Rev Neurother. 2011 Feb;11(2):165-83. doi: 10.1586/ern.10.193. Epub 2010 Dec 16.

Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.

N Engl J Med. 2006 Sep 14;355(11):1088-91. doi: 10.1056/NEJMp068159.

Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.

J Neurol Sci. 2011 Dec;311 Suppl 1:S29-34. doi: 10.1016/S0022-510X(11)70006-5.

New drugs may improve, complicate treatment for multiple sclerosis.

Nat Med. 2010 Mar;16(3):272. doi: 10.1038/nm0310-272.

Sudden unexpected death on fingolimod.

Mult Scler. 2012 Oct;18(10):1507-8. doi: 10.1177/1352458512438456. Epub 2012 Feb 2.

引用本文的文献

Expression of leukotriene B receptor 1 defines functionally distinct DCs that control allergic skin inflammation.

Cell Mol Immunol. 2021 Jun;18(6):1437-1449. doi: 10.1038/s41423-020-00559-7. Epub 2020 Oct 9.

Emerging oral immunomodulating agents - focus on teriflunomide for the treatment of multiple sclerosis.

Degener Neurol Neuromuscul Dis. 2012 Mar 10;2:15-28. doi: 10.2147/DNND.S29022. eCollection 2012.

Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases.

Manage Sci. 2018 Aug;64(8):3469-3970. doi: 10.1287/mnsc.2017.2793. Epub 2017 Aug 21.

Celastrol Ameliorates EAE Induction by Suppressing Pathogenic T Cell Responses in the Peripheral and Central Nervous Systems.

J Neuroimmune Pharmacol. 2015 Sep;10(3):506-16. doi: 10.1007/s11481-015-9598-9. Epub 2015 Mar 15.

New hope for multiple sclerosis patients.

ACS Chem Neurosci. 2013 Mar 20;4(3):368. doi: 10.1021/cn400059g.

MS Treatment Is on the Cusp of Something Big: On the Cusp of Something Big?

Biotechnol Healthc. 2012 Winter;9(4):24-7.

Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Br J Pharmacol. 2012 Apr;165(7):2044-58. doi: 10.1111/j.1476-5381.2011.01762.x.

Fingolimod (FTY720): First approved oral therapy for multiple sclerosis.

J Pharmacol Pharmacother. 2011 Jan;2(1):49-51. doi: 10.4103/0976-500X.77118.

Lipid phosphate phosphatase 3 enables efficient thymic egress.

J Exp Med. 2011 Jun 6;208(6):1267-78. doi: 10.1084/jem.20102551. Epub 2011 May 16.

Prevalence of celiac disease in multiple sclerosis.

BMC Neurol. 2011 Mar 7;11:31. doi: 10.1186/1471-2377-11-31.